File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Incidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study

TitleIncidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study
Authors
KeywordsCOVID-19
Incidence
Outcome
SARS-CoV-2
Issue Date2020
Citation
Seminars in Arthritis and Rheumatism, 2020, v. 50, n. 5, p. 885-889 How to Cite?
AbstractObjectives: Patients with rheumatologic diseases might be more susceptible to COVID-19 and carry a poorer prognosis. The aim of this study is to examine the incidence and outcomes of all COVID-19 patients with rheumatologic conditions in Hong Kong. Methods: This is a population-based retrospective study. All patients tested positive for SARS-CoV-2 by PCR with a previous diagnosis of rheumatologic diseases were reviewed. The incidence of COVID-19 in patients with rheumatologic conditions was calculated and compared to the general population in Hong Kong. Descriptive data of those rheumatologic patients with COVID-19 and the clinical course of the index infection were presented. Results: Up till 27 May 2020, there were 1067 cases of COVID-19 diagnosed in Hong Kong which had a population of 7.5 million. Out of the 39,835 patients with underlying rheumatologic diseases, we identified 5 PCR confirmed COVID-19 cases. The estimated incidence of COVID-19 was 0.0126% patients with rheumatologic diseases, compared to 0.0142% in the general population. All 5 patients had inflammatory arthropathies. One patient was on hydroxychloroquine and sulphasalazine, and one was on methotrexate. None of the 3534 patients on b/tsDMARDs was infected. Four patients had leucopenia/lymphopenia and stool viral PCR was positive in 3 patients. All patients made uneventful recovery without complications or flare of underlying diseases. Conclusions: We found no alarming signals of increased frequency or severity of COVID-19 in patients with rheumatologic diseases, although extrapolation of the results to other populations with different infection control strategies should be made with caution.
Persistent Identifierhttp://hdl.handle.net/10722/313128
ISSN
2023 Impact Factor: 4.6
2023 SCImago Journal Rankings: 1.721
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSO, Ho-
dc.contributor.authorMAK, Joyce Wing Yan-
dc.contributor.authorSO, Jacqueline-
dc.contributor.authorLUI, Grace-
dc.contributor.authorLUN, Frankie-
dc.contributor.authorLEE, Jolly-
dc.contributor.authorCHAN, Shirley-
dc.contributor.authorHO, Carmen-
dc.contributor.authorCHAN, Jacky Man Chun-
dc.contributor.authorKONG, Shing Pak-
dc.contributor.authorNG, Woon Leung-
dc.contributor.authorTAM, Lai Shan-
dc.date.accessioned2022-06-01T03:03:47Z-
dc.date.available2022-06-01T03:03:47Z-
dc.date.issued2020-
dc.identifier.citationSeminars in Arthritis and Rheumatism, 2020, v. 50, n. 5, p. 885-889-
dc.identifier.issn0049-0172-
dc.identifier.urihttp://hdl.handle.net/10722/313128-
dc.description.abstractObjectives: Patients with rheumatologic diseases might be more susceptible to COVID-19 and carry a poorer prognosis. The aim of this study is to examine the incidence and outcomes of all COVID-19 patients with rheumatologic conditions in Hong Kong. Methods: This is a population-based retrospective study. All patients tested positive for SARS-CoV-2 by PCR with a previous diagnosis of rheumatologic diseases were reviewed. The incidence of COVID-19 in patients with rheumatologic conditions was calculated and compared to the general population in Hong Kong. Descriptive data of those rheumatologic patients with COVID-19 and the clinical course of the index infection were presented. Results: Up till 27 May 2020, there were 1067 cases of COVID-19 diagnosed in Hong Kong which had a population of 7.5 million. Out of the 39,835 patients with underlying rheumatologic diseases, we identified 5 PCR confirmed COVID-19 cases. The estimated incidence of COVID-19 was 0.0126% patients with rheumatologic diseases, compared to 0.0142% in the general population. All 5 patients had inflammatory arthropathies. One patient was on hydroxychloroquine and sulphasalazine, and one was on methotrexate. None of the 3534 patients on b/tsDMARDs was infected. Four patients had leucopenia/lymphopenia and stool viral PCR was positive in 3 patients. All patients made uneventful recovery without complications or flare of underlying diseases. Conclusions: We found no alarming signals of increased frequency or severity of COVID-19 in patients with rheumatologic diseases, although extrapolation of the results to other populations with different infection control strategies should be made with caution.-
dc.languageeng-
dc.relation.ispartofSeminars in Arthritis and Rheumatism-
dc.subjectCOVID-19-
dc.subjectIncidence-
dc.subjectOutcome-
dc.subjectSARS-CoV-2-
dc.titleIncidence and clinical course of COVID-19 in patients with rheumatologic diseases: A population-based study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.semarthrit.2020.07.012-
dc.identifier.pmid32896705-
dc.identifier.pmcidPMC7377992-
dc.identifier.scopuseid_2-s2.0-85090183294-
dc.identifier.volume50-
dc.identifier.issue5-
dc.identifier.spage885-
dc.identifier.epage889-
dc.identifier.eissn1532-866X-
dc.identifier.isiWOS:000580602000014-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats